Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Total Liabilities (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Total Liabilities for 11 consecutive years, with $62.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 31.03% year-over-year to $62.5 million, compared with a TTM value of $62.5 million through Dec 2025, down 31.03%, and an annual FY2025 reading of $62.5 million, down 31.03% over the prior year.
  • Total Liabilities was $62.5 million for Q4 2025 at Spyre Therapeutics, up from $49.5 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $452.7 million in Q3 2023 and bottomed at $18.8 million in Q1 2023.
  • Average Total Liabilities over 5 years is $80.9 million, with a median of $55.6 million recorded in 2024.
  • The sharpest move saw Total Liabilities skyrocketed 1785.25% in 2023, then plummeted 79.3% in 2024.
  • Year by year, Total Liabilities stood at $26.0 million in 2021, then decreased by 19.8% to $20.8 million in 2022, then skyrocketed by 251.69% to $73.3 million in 2023, then rose by 23.73% to $90.7 million in 2024, then crashed by 31.03% to $62.5 million in 2025.
  • Business Quant data shows Total Liabilities for SYRE at $62.5 million in Q4 2025, $49.5 million in Q3 2025, and $83.1 million in Q2 2025.